Clinical trial NCT05137483: Cognitive Impairment and Upper Extremity Performance in COPD
Official title: Comparison of Upper Extremity Functional Capacity, Respiratory Functions, Fatigue and Quality of Life in Chronic Obstructive Pulmonary Patients With and Without Cognitive Impairment
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: COPD
Upper Extremity
Upper Limb Function
Cognitive Impairment
Keywords: copd
cognitive impairment
cognition
upper extremity
Lead sponsor: Izmir Katip Celebi University
Sponsor class: OTHER
First posted: 2021-11-30
Enrollment: 80
Sex: ALL
Minimum age (years): 45
Standard ages: ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: COPD patients above 45 years

Brief summary: Within the scope of this study, COPD patients will be divided into two groups according to cognitive dysfunction.

Pulmonary function test, COPD assessment scale, Mini-Mental State Examination and Montreal Cognitive Assessment Scale, 6 min pegboard ring test, grip strength measurement, Fatigue Impact Scale and St.George Respiratory Questionnaire will be applied to the groups.

Detailed description: Although the mechanism of cognitive dysfunction in COPD is not clear, the reasons focused on are; decreased oxygen use, high carbon dioxide levels, increased inflammation and oxidative stress, decreased physical activity, peripheral vascular diseases, atherosclerosis, high or low blood pressure, cerebral vasoconstriction, increased intracranial pressure, accompanying comorbidities, smoking and genetic predisposition, brain damage and exacerbations have been reported. Few studies have shown that cognitive dysfunction is associated with functional performance. There are no studies on the effect of cognitive function on upper extremity performance and mechanisms of action in COPD patients.

The aim of this study is to compare upper extremity functional capacities, respiratory functions, fatigue and quality of life in COPD patients with and without cognitive function impairment.

Within the scope of this study, COPD patients will be divided into two groups according to cognitive dysfunction.

Pulmonary function test, COPD assessment scale, Mini-Mental State Examination and Montreal Cognitive Assessment Scale, 6 min pegboard ring test, grip strength measurement, Fatigue Impact Scale and St.George Respiratory Questionnaire will be applied to the groups.

Eligibility criteria: Inclusion Criteria:

* Volunteering to participate in the study
* Stage 2-3-4 according to the GOLD classification in the 40-65 age range

Exclusion Criteria:

* Exacerbation of respiratory symptoms in the past 4 weeks (change in breathlessness and/or sputum volume/color, need for antibiotic treatment or need for hospitalization)
* Presence of asthma, unstable coronary heart disease, uncontrolled diabetes, hypertension, left-sided congestive heart failure, neoplasia, severe claudication, encephalitis or epilepsy
* Having a history of head trauma or brain tumor
* Having a significant psychiatric condition or the presence of defined dementia, according to the American Psychiatric Association

Primary outcomes:
measure: 6 min. pegboard ring test
timeFrame: 6 minutes
Secondary outcomes:
measure: Mini Mental State Test
timeFrame: 15 minutes
measure: Montreal Cognitive Assessment Scale
timeFrame: 30 minutes
measure: Respiratory Function Test
timeFrame: 20 minutes
measure: Fatigue Impact Scale
timeFrame: Time Frame: 20 minutes
measure: St. George Respiratory Questionnaire
timeFrame: 20 minutes
measure: COPD Assessment Test
timeFrame: 10 minutes
measure: mMRC Dyspnea Scale
timeFrame: 5 minutes
Other outcomes:
Locations:
Study officials:
References: